In gliomas, GSK-3β is downregulated; its overexpression inhibits angiogenesis and tumor growth by upregulating the β-catenin and mTOR/p70S6K1 pathways [47], and also restores cell differentiation [48]. This evidence concerns the gene GSK3B and central nervous system cancer.